|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's Range||85.81 - 86.40|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||80.30|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.25 (2.61%)|
|1y Target Est||91.47|
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Eli Lilly and Company (NYSE:LLY) as an investment opportunity by takingRead More...
INDIANAPOLIS, June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity® (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data.1,2 These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions® in Orlando. Trulicity is Eli Lilly and Company's (LLY) once-weekly, injectable GLP-1 RA approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity is available in 0.75 mg and 1.5 mg and should be used along with diet and exercise.
INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog®. URLi is Lilly's novel mealtime insulin currently in phase 3 development. Two of the studies evaluated URLi administered through multiple daily injections in people with type 1 and type 2 diabetes to understand the differences in the pharmacokinetics (the amount of insulin in the blood) and pharmacodynamics (how insulin works to control blood glucose levels) between URLi and Humalog.
- In separate analysis, Jardiance (empagliflozin) reduced risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start ...
Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, ...
INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity® (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes.1 Data from this Phase 2 study will be presented for the first time today in an oral session at the American Diabetes Association's (ADA) 78th Scientific Sessions® in Orlando. Trulicity is Eli Lilly and Company's (LLY) once-weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonist (RA) approved to improve blood sugar (glucose) in adults with type 2 diabetes.
While the Trump administration touts its efforts to lower drug prices with its "blueprint," the debate over how drugs are priced and how high those prices are in the U.S. picks up speed. Patient groups elected officials and the American Medical Association are now calling on drug companies to explain how they arrive their prices for insulin. Part of the challenge for diabetics is that there is no generic form of insulin on the U.S. market.
Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India's Dr. Reddy's Laboratories from launching generics until the patent expires. The patent for Lilly's top-selling cancer drug will expire in May 2022.
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by a competitor that had stated its intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022. The ruling came in the case of Eli Lilly and Company v. Dr. Reddy's Laboratories. "We are pleased with today's District Court ruling finding the Alimta vitamin regimen patent would be infringed by the competitor's proposed products," said Michael J. Harrington, Lilly's senior vice president and general counsel.
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (ARMO). Lilly's tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per share in cash, expired as scheduled on Thursday, June 21, 2018. As of the expiration of the tender offer, 27,542,054 shares of ARMO common stock were validly tendered and not properly withdrawn, representing approximately 90.6 percent of the shares of ARMO common stock outstanding, and have been accepted for payment under the terms of the tender offer.
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
North Chicago, Illinois-based AbbVie Inc.'s stock finished Wednesday's session 0.24% higher at $98.25 with a total trading volume of 4.68 million shares. The Company's shares have advanced 37.95% over the past year.
Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.
Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline. Of these, Eylea continues to be the major revenue driver for Regeneron in 2018. Wall Street analysts expect Regeneron to report revenue of close to $6.3 billion in 2018, a YoY (year-over-year) rise of ~7.6%.
Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
INDIANAPOLIS , June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.5625 per share on outstanding common ...
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Ricks says pharmacy benefit managers, or PBMs, are benefiting from price increases. "With the adoption of high-deductible plans, patients are subjected to the list price," said Ricks, who was in Minneapolis for the Piper Jaffray Heartland Summit, an annual health-care conference.